Originally published by Win Warfield in TriGemX Bio on November 9, 2026. Read the original release.
TriGemX Bio has appointed biotechnology industry veteran Daniel Lynch chairman of its board of directors as the company advances its Phase 3 migraine treatment candidate and prepares for a proposed business combination with TCGX Acquisition Corp. (Nasdaq: TCGX).
Lynch will continue serving as chairman following the closing of the previously announced transaction, which would combine TriGemX with the publicly traded special purpose acquisition company.
About Daniel Lynch
He brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industries, including executive positions, board appointments and involvement in the development and commercialization of new therapies.
Lynch currently serves as an executive venture partner at GV, formerly Google Ventures, and chairman of Beeline Medicines and Delphia Therapeutics. He is also a director of Cardurion Pharmaceuticals.
Previously, he held board or executive chairman positions at several biotechnology companies, including Blueprint Medicines, SpringWorks, Translate Bio, Surface Oncology, Xilio Therapeutics and Stromedix.
Earlier in his career, Lynch served as CEO and CFO of ImClone Systems, where he helped lead a corporate turnaround and secured FDA approval of the cancer therapy Erbitux.
He also spent more than 15 years in financial leadership roles at Bristol Myers Squibb.
“We are delighted to welcome Dan to our Board of Directors, and I am thrilled to be working with him once again,” said Jeff Goater, CEO of TriGemX Bio. “His extensive experience and strategic insights will be invaluable as we advance the development of elismetrep and prepare TriGemX for its next phase of growth.”
About TriGemX
TriGemX is developing elismetrep, a potential first-in-class treatment for migraine that targets TRPM8, an ion channel involved in neural signaling.
The drug candidate is currently undergoing Phase 3 clinical trials for the acute treatment of migraine, with results from the first Phase 3 study expected in mid-2027.
“TriGemX’s potential first-in-class migraine candidate, elismetrep, which targets TRPM8, represents an entirely new approach to the treatment of migraine,” Lynch said.
The board appointment comes as TriGemX works toward completing its proposed combination with TCGX Acquisition Corp., a special purpose acquisition company sponsored by an affiliate of TCG Crossover Management.
Source: Win Warfield, TriGemX Bio on November 9, 2026. Republished with credit to the original author. Read the original release.
